Nephrology Team Grants :: Nationwide Children's Hospital

contact info

Nationwide Children's Hospital
700 Children's Drive
Columbus, Ohio 43205
Phone: (614) 722-4360
Dialysis Services: (614) 722-4850
Fax: (614) 722-6482


Request an appointment

View location on a map

US News and World Report

Pulmonary Medicine ranked #7 in US News and World Report.

View the full list of Nationwide Children's Hospital's rankings »

Nephrology Team Grants

Nuclear Receptor and MAP Kinase Signaling in Podocyte Injury (R01) 

  • R01 DK095059-01-A1 (William E. Smoyer) 07/1/2013 - 08/24/2018 
  • NIH-NIDDK $218,941 
The goal of this project is to define specific molecular signaling pathways able to regulate podocyte injury in NS to develop more targeted and less toxic therapies for NS. The objective is to determine the ability of the glucocorticoid receptor (GR), peroxisome proliferator-activated receptor g (PPARg), and MAPK signaling pathways to regulate podocyte injury, and to exploit this knowledge to develop more effective novel therapies for NS. 
 

Integrative Proteomics & Metabolomics for Pediatric Glomerular Disease Biomarkers 

  • UM1 DK 100866-01 (William E. Smoyer) 9/16/2013-3/24/2017 
  • NIH-NIDDK $394,163 
The overall objective of this proposal is to successfully recruit 600 children with four glomerular diseases (Minimal Change Nephrotic Syndrome [MCNS], Focal Segmental Glomerulosclerosis [FSGS], IgA Nephropathy [IgAN], and Idiopathic Membranous Nephropathy [IMN]) into a three-year longitudinal cohort study that will include integrated proteomic and metabolic analyses of highly phenotyped biological samples to identify predictive biomarkers for pediatric glomerular disease. 
 

Rituximab against Mycophenolate Mofetil in Children with Refractory Nephrotic Syndrome (RAMP Study) 

  • Investigator-Initiated Clinical Trial (William E. Smoyer) 12/1/2013-11/30/2016 
  • Genentech Corporation 
The goal of this study is to test the hypothesis that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children who have had one relapse while receiving MMF using a randomized, multi-center clinical trial to directly compare the ability of MMF and Rituximab to maintain remission for 6 months in children with SDNS and FRNS. 
 

Genetic Variations and Development of Vesicoureteral Reflux and Sequelae 

  • 1RC4DK090937 (Andrew L. Schwaderer & David Hains) 9/30/2010 – 9/29/2013
  • NIH-NIDDK $1,277,277 
By determining the role of antibiotic proteins in the urinary system’s defense against infection, we will determine if these antibiotic proteins can be used to identify or treat people at risk for urinary tract infections. Also, we will investigate potential genetic causes of vesicoureteral reflux. 
 

The Role of microRNA in Congenital Obstructive Nephropathy

  • K08 DK092340 (Sue Ingraham) 09/1/2011 - 12/24/2014                 
  • NIH-NIDDK $149,472
  • Nuclear Receptor and MAP Kinase Signaling in Podocyte Injury (R01)
The long-term objectives of the research project are to improve the care of pediatric patients with congenital obstructive nephropathy by identifying effective early biomarkers for the diagnosis and prognosis of congenital obstructive nephropathy, as well as elucidating novel therapeutic targets for this devastating condition.
 

Ribonuclease7: Antimicrobial Activity in the Human Kidney and Urinary Tract 

  • K08 DK094970-02 (John David Spencer) 08/01/2012 – 08/31/2017
  • NIH-NIDDK $676,851.00 
The goal of this proposal is to study the structure, function, and biological relevance of ribonuclease 7, a novel AMP that has potent antimicrobial properties in the human urinary tract. 
Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000